Clinical Trials Using Gedatolisib

Clinical trials are research studies that involve people. The clinical trials on this list are studying Gedatolisib. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-2 of 2
  • Talazoparib and Gedatolisib in Treating Patients with Advanced Triple Negative or BRCA1 / 2 Positive, HER2 Negative Breast Cancer

    This phase I / II trial studies the best dose of talazoparib when given together with gedatolisib and to see how well they work in treating patients with triple negative or BRCA1 / 2 positive, HER2 negative breast cancer that has spread to other places in the body (advanced) and cannot be removed by surgery. Talazoparib and gedatolisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Talazoparib blocks an enzyme called PARP. Talazoparib causes cancer cells to die by breaking the tumor DNA and then stopping the tumor from repairing the damaged DNA. Gedatolisib blocks two receptors called PI3K and mTOR. By blocking these pathways, gedatolisib may cause cancer cells to die and stop growing.
    Location: 5 locations

  • Palbociclib and Gedatolisib in Treating Patients with Advanced Solid Tumors or Lung, Pancreatic, or Head and Neck Cancer

    This phase I trial studies the side effects and best dose of palbociclib and gedatolisib and how well they work in treating patients with solid tumors or lung, pancreatic, or head and neck cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment. Palbociclib and gedatolisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 4 locations